Humana (NYSE:HUM) Price Target Lowered to $201.00 at Cantor Fitzgerald

Humana (NYSE:HUM) had its price objective trimmed by Cantor Fitzgerald from $290.00 to $201.00 in a report issued on Thursday, Marketbeat Ratings reports. The firm currently has a neutral rating on the insurance provider’s stock.

HUM has been the topic of several other reports. Jefferies Financial Group dropped their price objective on shares of Humana from $313.00 to $310.00 and set a “buy” rating on the stock in a report on Monday, January 26th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $344.00 price target on shares of Humana in a research report on Tuesday, January 6th. Barclays reissued an “underperformer” rating on shares of Humana in a report on Monday, January 5th. Royal Bank Of Canada lowered Humana from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $322.00 to $189.00 in a report on Thursday. Finally, Guggenheim reduced their price target on Humana from $312.00 to $252.00 and set a “buy” rating for the company in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus price target of $248.64.

Humana Stock Performance

Shares of HUM opened at $178.99 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.00. The stock has a 50-day moving average of $246.13 and a two-hundred day moving average of $261.18. The stock has a market cap of $21.53 billion, a P/E ratio of 18.23, a P/E/G ratio of 1.95 and a beta of 0.44. Humana has a one year low of $169.61 and a one year high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the business posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, research analysts predict that Humana will post 16.47 EPS for the current year.

Institutional Trading of Humana

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Montag A & Associates Inc. increased its holdings in Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. CoreCap Advisors LLC grew its position in shares of Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Fideuram Asset Management Ireland dac acquired a new stake in shares of Humana in the fourth quarter valued at about $27,000. Rosenberg Matthew Hamilton increased its stake in shares of Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Humana during the 2nd quarter worth about $32,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Q4 results marginally beat expectations: Humana reported EPS of ($3.96) vs. consensus ($4.01) and revenue of $32.64B, with revenue up ~11% year/year — evidence the business still has top‑line momentum. Humana Reports Fourth Quarter 2025 Financial Results
• Positive Sentiment: Medicare Advantage membership is growing fast and CenterWell continued to drive revenue — management flagged a ~25% MA membership increase for 2026, which supports medium‑term growth expectations even as margins recover. Humana outlines 25% Medicare Advantage membership growth
• Neutral Sentiment: Some analysts remain constructive or neutral after the print — Jefferies kept a Buy stance while lowering its target to $235 (still well above the current price), creating a counterbalance to the downgrades. Jefferies lowers price target to $235
• Neutral Sentiment: TD Cowen maintained a Hold with a $173 target, signaling cautious tone from some Street strategists even as views diverge. TD Cowen Hold rating
• Negative Sentiment: FY‑2026 guidance was cut materially: Humana set EPS guidance of 9.00 vs. the Street ~12.03, citing lower quality Star Ratings and margin pressure — the guidance shortfall is the principal driver of the recent selloff and investor concern. Humana forecasts 2026 profit below estimates (Reuters)
• Negative Sentiment: Q4 GAAP loss widened and margins are under stress from rising MA medical costs and Star Ratings pressure — investors are focused on near‑term profitability risk even as membership rises. Humana Reports $796 Million Loss (Forbes)
• Negative Sentiment: Multiple firms cut price targets and slashed forecasts after the results and outlook — Evercore, Leerink, Cantor and others trimmed targets (some now near or below the stock), increasing downside risk from analyst revisions. Analysts slash forecasts after Q4 (Benzinga)
• Negative Sentiment: Shares recently hit a 52‑week low after the weak outlook; today’s uptick appears to be a short‑term rebound as investors parse the offset between growth and profit risk. Humana hits 52-week low (Benzinga)

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.